Journal article
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
Abstract
BackgroundOverexpression/activation of focal adhesion kinase (FAK) in human malignancies has led to its evaluation as a therapeutic target. We report the first-in-human phase I study of BI 853520, a novel, potent, highly selective FAK inhibitor.ObjectiveOur objectives were to identify the maximum tolerated dose (MTD), and to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), biomarker expression, and preliminary activity.Patients …
Authors
de Jonge MJA; Steeghs N; Lolkema MP; Hotte SJ; Hirte HW; van der Biessen DAJ; Abdul Razak AR; De Vos FYFL; Verheijen RB; Schnell D
Journal
Targeted Oncology, Vol. 14, No. 1, pp. 43–55
Publisher
Springer Nature
Publication Date
February 2019
DOI
10.1007/s11523-018-00617-1
ISSN
1776-2596